







In 2011, the landmark HIV Pre-
vention Trials Network (HPTN) 052
trial found that early initiation of anti-
retroviral treatment (ART) in persons
living with HIV (PLHIV) reduced viral
transmission to uninfected partners by
96%.1 Treatment as prevention (TasP),
whereby HIV transmission is prevented
by consistent use of HIV treatment and
durable viral suppression, has ushered in
a new era in worldwide HIV preven-
tion.2 The combined health benefits of
averting new infections and preserving/
improving health for PLHIV have trans-
lated into rapid scale-up in treatment
access across the globe.3
Eight years after the publication of
HPTN 052 results and 3 years after the
launch of the Undetectable = Untrans-
mittable (U = U) campaign,4 promotion
of TasP has largely been adopted into
global HIV discourse and policy. How-
ever, dissemination of information about
TasP/U = U to communities in the most
impacted areas of the world has been
delayed, incomplete, or ineffective. For
example, qualitative research we con-
ducted in 2015 with rural South African
men in Mpumalanga Province showed
low awareness of the potential of treat-
ment to reduce transmission to partners.5
Moreover, both PLHIV and those at risk
of HIV believed this information would
have played a significant role in their
choices to get tested, initiate treatment,
and disclose to their partners.5 The few
other studies assessing TasP awareness
in sub-Saharan Africa (SSA) have also
found levels to be remarkably low.6,7
Health providers are the primary
gateway for delivering HIV prevention
and treatment information. However,
virtually no research has assessed pro-
vider knowledge, attitudes, and counsel-
ing practices related to TasP/U = U.
Therefore, we asked health providers
about TasP during a 2018 assessment
of 9 health facilities, conducted as part
of a cluster-randomized trial underway
in South Africa examining community
mobilization around improving HIV
care and treatment (NCT02197793).8
Interviews were designed to understand
provider attitudes, beliefs, and counsel-
ing behaviors about the potential of
ART to avert new infections.
METHODS
Primary care facility assessments
were undertaken in all 9 public health
facilities located within the Agincourt
health and socio-demographic surveil-
lance system, a census area in northeast
South Africa. We created rosters of all
staff in each facility and then randomly
selected a sample of 10 staff from each
clinic, except for one that had only 9. Of
89 selected staff, 79 providers under-
went structured interviews to understand
practices related to HIV care provision,
3 failed to participate, and 7 did not
provide care and were excluded from this
analysis. To assess providers’ under-
standing of TasP, we asked them to agree
or disagree with the statement: “Individ-
uals who adhere to ART and are virally
suppressed have a very low chance of
transmitting HIV to their sex partner
during unprotected sex.” We also asked
about the frequency (always, sometimes,
or never) with which providers told their
clients that onward transmission was
unlikely if virally suppressed. Finally,
we included separate questions about
whether providers counsel PLHIV who
are virally suppressed that they do not
need to use condoms with partners who
are HIV-positive, HIV-negative, and
unknown status. Questions were pilot
tested for clarity at 1 facility before use.
We compared provider character-
istics and counseling practices by
knowledge of TasP, assessing associa-
tions using the F statistic (converted
from the x2 statistic, corrected for survey
design) for binary and categorical vari-
ables and linear regression for continu-
ous variables. Analyses were clustered
by facility and weighted based on sam-
pling probability from the clinic roster.
We also calculated the intraclass corre-
lation of responses by clinic using an
unadjusted random intercept model to
determine to what extent variance was
due to within- vs. between-clinic differ-
ences. We presented assessment results
at study clinics approximately 6 months
after the interviews to seek feedback and
interpretation of findings.
RESULTS
Table 1 characterizes the 79 pro-
viders, most of whom (83%) were
women. About half (48%) were pro-
fessional nurses, followed by staff
nurses (19%), home-based care (18%),
and lay counselors (14%). On average,
the providers had 8 years of profes-
sional experience and 5 years in their
current clinic.
Providers demonstrated incon-
sistent knowledge and infrequent
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31% of providers who did not reported
telling virally suppressed clients that
they did not need to use condoms with
partner of any serostatus, indicating
a lack of understanding of TasP among
providers and that TasP knowledge had
little impact on counseling behavior.
The intraclass correlation for TasP
knowledge/agreement was 0.076,
indicating minimal clustering of re-
sponses by clinic.
During feedback meetings, 3 of 9
clinic operational managers (who are
also providers) stated no knowledge of
TasP; providers in 2 clinics disputed
the idea of counseling on TasP because
of concerns around reduced
condom use.
DISCUSSION
Less than half of the providers we
surveyed in rural South Africa in 2018
were knowledgeable about TasP, and
even fewer understood the nuances of
counseling around undetectable viral
load and HIV transmission. Even those
who agreed with TasP infrequently
shared this information with patients.
The findings indicate that Tasp/U = U
messaging is not routinely reaching
PLHIV and that providers themselves
are not fully informed about the public
health benefits of TasP. This is a small
study with and collected from 9 clinics
in a single rural area of Mpumlanga; as
such, findings cannot be generalized to
other facilities and areas of the country.
TABLE 1. Provider Characteristics and Reported Knowledge and Counseling About TasP, 2018
N
All
Providers (N = 79)
Providers Who Know
About TasP (N = 33)
Providers Who Do not
Know About TasP (N = 46) P
Sex 79 Weighted N (column %) 0.06
Men 13 (17%) 7 (22%) 6 (13%)
Women 66 (83%) 26 (78%) 40 (87%)
Cadre* 79 0.13
Professional nurse 38 (48%) 12 (37%) 26 (57%)
Staff nurse 15 (19%) 10 (30%) 5 (11%)
Lay counselor 11 (14%) 8 (23%) 3 (7%)
Home-based care 14 (18%) 4 (11%) 11 (24%)
Other (occupational therapist and pharmacist) 1 (1%) 0 (0%) 1 (2%)
Years of professional experience, mean 6 SD† 77 8.3 6 6.4 9 6 7.5 7.8 6 5.6 0.56
Years in clinic, mean 6 SD† 76 5 6 3.5 6.4 6 3.7 4 6 3 0.05
How often do you tell your HIV-positive patients that if
they adhere to ART and are virally suppressed they
will have a very low chance of transmitting HIV to
their partner?
79 0.13
Never 27 (35%) 7 (20%) 21 (45%)
Sometimes 8 (10%) 6 (19%) 2 (4%)
Always 43 (55%) 20 (61%) 23 (51%)
Do you tell your HIV-positive patients that if they are
virally suppressed they do not need to use a condom
with a partner who is HIV-positive?
79 0.01
Yes 17 (22%) 2 (7%) 14 (31%)
No 62 (78%) 31 (93%) 32 (69%)
Do you tell your HIV-positive patients that if they are
virally suppressed they do not need to use a condom
with a partner who is HIV-negative?
79 0.06
Yes 17 (22%) 3 (9%) 14 (31%)
No 62 (78%) 30 (91%) 32 (69%)
Do you tell your HIV-positive patients that if they are
virally suppressed they do not need to use a condom
with a partner of unknown HIV status?
79 0.06
Yes 17 (22%) 3 (9%) 14 (31%)
No 62 (78%) 36 (91%) 26 (69%)
Numbers are weighted based on sampling probability and may not sum to total due to rounding of weighted Ns.
*There are no doctors on staff in the primary clinics and community health centers; doctors make intermittent visits subject to transport availability.
†Total N reflects nonresponse on selected survey items.
counseling on the benefits of TasP. 
Fewer than half (42%) of providers 
indicated an awareness of the benefits 
of TasP. Male providers, and pro-
viders who had been at their current 
clinic longer, were slightly more 
likely to know about TasP (P = 0.06  
and P = 0.05, respectively). Among 
the providers who knew of TasP, only 
61% said they always shared this 
information with their HIV-positive 
clients; 20% never shared TasP infor-
mation with clients. The large major-
ity of providers (78%–79%) reported 
counseling virally suppressed patients 
to always use condoms, regardless of 
their partner’s status. Less than 10% of 
providers who knew about TasP and
However, this is also among the first
inquiries into provider knowledge and
counseling behavior around TasP in
a high prevalence region where inroads
with U = U messaging could have
large implications.
There is little published research
on providers’ attitudes toward TasP or U
= U in low- and middle-income coun-
tries to date. Work in SSA around safe
conception in discordant couples has
found that providers often have inade-
quate knowledge of discordance9 and/or
may choose to withhold information
about HIV transmission risks when vir-
ally suppressed due to concerns that
clients would make poor choices if they
had this information.9,10 Researchers
have also reported that providers
prioritize minimizing risk (eg, condoms-
only prevention messaging) and have
a high degree of discomfort providing
information about ART use for safer
conception to clients living with
HIV.11,12 Similarly, research on pre-
exposure prophylaxis in SSA has found
that providers are far more comfortable
with condom promotion and have con-
cerns around increases in risk behavior
associated with reduced perceptions of
transmissibility.13,14 Our findings that
providers rarely counsel patients about
TasP may be attributed to similar con-
cerns about behavioral disinhibition, with
some providers stating as much during
feedback discussions.
Although providers may have
doubts about engaging with TasP messag-
ing, there are numerous reasons why
patients should be informed about the
clinical and public health benefits of viral
suppression. Most importantly, individuals
have the right to understand and be able to
make informed decisions about their
health and treatment choices. In addition,
research has indicated that knowledge
about TasP could encourage people to
seek HIV testing and adhere to treatment,
particularly to prevent transmission to
their partners.5 Understanding TasP can
also address stigma, minimize fears about
transmissibility to partners, and allow
partners to have sexual relationships and
achieve their fertility intentions free of the
fear of onward transmission.15,16
Ensuring widespread, accurate
messaging about TasP/U = U may
require multiple steps. First, language
around TasP/U = U needs to be incorpo-
rated into relevant policy documents and
training programs for providers. Current
policy, including the South African HIV
service delivery guidelines,17 more recent
directives on Test and Treat,18 and the
National Strategic Plan,19 has no guid-
ance for counseling around TasP; TasP is
mentioned only as a component of
combination prevention and again in the
glossary.19 Without specific guidance,
simple messaging, and training, providers
may not be aware of TasP or, as found in
our data, not share TasP information even
when they are aware. Second, providers
need additional training on the topics of
serodiscordance, safer contraception, and
behavioral disinhibition to deter sharing
obsolete prevention messages. Third, it is
critical that viral load monitoring be
conducted regularly and that results are
returned promptly to inform HIV clinical
management, ensuring that patients on
treatment are, in fact, suppressed. TasP
counseling requires a nuanced under-
standing of transmission dynamics and
consistent clinical monitoring,16 a chal-
lenge in settings such as South Africa
with no linked national medical record
system and high levels of labor migra-
tion. Finally, successful TasP/U = U
messaging has often been led by civil
society. Although a small number of
South African non-governmental organ-
izations have signed on to the U = U
consensus statement,20 further advocacy
and leadership in vocalizing patients’
rights to TasP information and its poten-
tial for supporting HIV service uptake
could help stimulate government and
provider attention.
Informing patients and communi-
ties about TasP can ultimately help
South Africa and other highly impacted
countries meet their HIV treatment tar-
gets and get closer to ending the epi-
demic. Moving forward we recommend
more in-depth monitoring of TasP/U =
U counseling behaviors among pro-
viders, not only through validating this
tool or others, but also through more
detailed assessments of provider behav-
iors (eg, direct observation or standard-
ized patients). It may take time for
providers to internalize new, evidence-
informed messaging around TasP, and
this is unlikely to occur until national
guidance and training programs provide
direction and support to providers. Prog-
ress may also require civil society to
champion this critical issue.
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